ReviewArteriosclerosis, thrombosis, and vascular biology2016
Regression of Atherosclerosis: The Journey From the Liver to the Plaque and Back.
Review in Arteriosclerosis, thrombosis, and vascular biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 54 citations in OpenAlex.
- Efferocytosis activates a DNMT3A-mediated oxidized DNA repair pathway to enable tissue resolution.The Journal of clinical investigation · 2026Article
- Impaired Glycolysis Leads to Defective Efferocytosis and Impaired Plaque Resolution inCirculation · 2026Article
- Itaconate alleviates cholesterol burden via ABCA1 stabilization and cholesterol efflux.Atherosclerosis · 2025Article
- Development of Pro-resolving and Pro-efferocytic Nanoparticles for Atherosclerosis Therapy.ACS pharmacology & translational science · 2024Article
- The Role of Macrophages in Atherosclerosis: Pathophysiologic Mechanisms and Treatment Considerations.International journal of molecular sciences · 2023Review
- Article
- There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness.American journal of preventive cardiology · 2022Review
- KLF2 alleviates endothelial cell injury and inhibits the formation of THP‑1 macrophage‑derived foam cells by activating Nrf2 and enhancing autophagy.Experimental and therapeutic medicine · 2022Article
- PLTP deficiency-mediated atherosclerosis regression could be related to sphinogosine-1-phosphate reduction.Atherosclerosis · 2022Article
- Through the layers: how macrophages drive atherosclerosis across the vessel wall.The Journal of clinical investigation · 2022Review
- Sphingolipids and Cholesterol.Advances in experimental medicine and biology · 2022Article
- Efferocytosis induces macrophage proliferation to help resolve tissue injury.Cell metabolism · 2021Article
- Cardiovascular disease in diabetes, beyond glucose.Cell metabolism · 2021Review
- Reduction of TMAO level enhances the stability of carotid atherosclerotic plaque through promoting macrophage M2 polarization and efferocytosis.Bioscience reports · 2021Article
- Inducible phospholipid transfer protein deficiency ameliorates atherosclerosis.Atherosclerosis · 2021Article
- Reshaping of the gastrointestinal microbiome alters atherosclerotic plaque inflammation resolution in mice.Scientific reports · 2021Article
- GSK3 modulation in acute lung injury, myocarditis and polycystic kidney disease-related aneurysm.Biochimica et biophysica acta. Molecular cell research · 2020Review
- Regression of Atherosclerosis in ApoE-/- Mice Via Modulation of Monocyte Recruitment and Phenotype, Induced by Weekly Dosing of a Novel "Cytotopic" Anti-Thrombin Without Prolonged Anticoagulation.Journal of the American Heart Association · 2020Article
- Atherosclerosis: Making a U Turn.Annual review of medicine · 2020Review
- Human amnion mesenchymal stem cells attenuate atherosclerosis by modulating macrophage function to reduce immune response.International journal of molecular medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Cardinal events in atherogenesis are the retention of apolipoprotein B-containing lipoproteins in the arterial wall and the reaction of macrophages to these particles. My laboratory has been interested in both the cell biological events producing apolipoprotein B-containing lipoproteins, as well as in the reversal of the damage they cause in the plaques formed in the arterial wall. In the 2013 George Lyman Duff Memorial Lecture, as summarized in this review, I covered 3 areas of my past, present, and future interests, namely, the regulation of hepatic very low density lipoprotein production by the degradation of apolipoprotein B100, the dynamic changes in macrophages in the regression of atherosclerosis, and the application of nanoparticles to both image and treat atherosclerotic plaques.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.